Rigel Pharmaceuticals, Inc. (RIGL): Price and Financial Metrics

Rigel Pharmaceuticals, Inc. (RIGL): $0.83

0.15 (+21.84%)

POWR Rating

Component Grades














  • RIGL scores best on the Quality dimension, with a Quality rank ahead of 85.5% of US stocks.
  • The strongest trend for RIGL is in Growth, which has been heading up over the past 179 days.
  • RIGL's current lowest rank is in the Stability metric (where it is better than 3.48% of US stocks).

RIGL Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for RIGL is -4.51 -- better than only 2.99% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 40.99 for RIGEL PHARMACEUTICALS INC; that's greater than it is for 99.05% of US stocks.
  • Over the past twelve months, RIGL has reported earnings growth of 699.35%, putting it ahead of 97.39% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to RIGEL PHARMACEUTICALS INC are AZYO, INTZ, PBYI, ARAY, and EXTR.
  • Visit RIGL's SEC page to see the company's official filings. To visit the company's web site, go to www.rigel.com.

RIGL Valuation Summary

  • RIGL's price/sales ratio is 1.5; this is 25% lower than that of the median Healthcare stock.
  • RIGL's price/sales ratio has moved down 2.6 over the prior 243 months.

Below are key valuation metrics over time for RIGL.

Stock Date P/S P/B P/E EV/EBIT
RIGL 2022-11-25 1.5 -6.5 -1.6 -1.8
RIGL 2022-11-23 1.5 -6.6 -1.6 -1.8
RIGL 2022-11-22 1.5 -6.8 -1.6 -1.9
RIGL 2022-11-21 1.5 -6.8 -1.6 -1.9
RIGL 2022-11-18 1.5 -6.6 -1.6 -1.8
RIGL 2022-11-17 1.4 -6.5 -1.6 -1.8

RIGL Growth Metrics

    Its 2 year price growth rate is now at 26.53%.
  • Its 2 year net income to common stockholders growth rate is now at -202.5%.
  • Its 4 year net income to common stockholders growth rate is now at 59.47%.
RIGL's revenue has moved up $30,085,000 over the prior 33 months.

The table below shows RIGL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 89.373 -70.935 -82.615
2022-06-30 88.506 -67.931 -84.53
2022-03-31 84.953 0.196 -84.859
2021-12-31 149.236 5.878 -17.914
2021-09-30 147.277 9.392 -14.51
2021-06-30 144.123 0.207 -7.732

RIGL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RIGL has a Quality Grade of B, ranking ahead of 89.87% of graded US stocks.
  • RIGL's asset turnover comes in at 0.825 -- ranking 30th of 682 Pharmaceutical Products stocks.
  • GERN, NEOG, and VNDA are the stocks whose asset turnover ratios are most correlated with RIGL.

The table below shows RIGL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.825 0.994 -0.082
2021-06-30 0.886 0.994 -0.034
2021-03-31 0.912 0.992 -0.069
2020-12-31 0.844 0.992 -0.296
2020-09-30 0.765 0.993 -0.259
2020-06-30 0.739 0.991 -0.220

RIGL Price Target

For more insight on analysts targets of RIGL, see our RIGL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.33 Average Broker Recommendation 1.33 (Strong Buy)

RIGL Stock Price Chart Interactive Chart >

Price chart for RIGL

RIGL Price/Volume Stats

Current price $0.83 52-week high $3.52
Prev. close $0.68 52-week low $0.64
Day low $0.82 Volume 60,093,600
Day high $0.99 Avg. volume 3,680,016
50-day MA $0.86 Dividend yield N/A
200-day MA $1.68 Market Cap 144.06M

Rigel Pharmaceuticals, Inc. (RIGL) Company Bio

Rigel Pharmaceuticals, Inc. engages in the discovery and development of small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders. The company was founded in 1996 and is based in South San Francisco, California.

RIGL Latest News Stream

Event/Time News Detail
Loading, please wait...

RIGL Latest Social Stream

Loading social stream, please wait...

View Full RIGL Social Stream

Latest RIGL News From Around the Web

Below are the latest news stories about RIGEL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RIGL as an investment opportunity.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a favorite amongst institutional investors who own 72%

To get a sense of who is truly in control of Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ), it is important to understand...

Yahoo | November 12, 2022

Rigel Announces Publication of Early Clinical Data of Olutasidenib in The Lancet Haematology

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the publication of data in The Lancet Haematology, which summarizes the Phase 1 results of the Phase 1/2 study of olutasidenib, an investigational, oral, small molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1). Olutasidenib was assessed as a monotherapy or in combination with azacitidine, in patients with mIDH1 acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The published data suggest that olutasidenib, with

Yahoo | November 10, 2022

Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Lags Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 15.38% and 1.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 3, 2022

Rigel Reports Third Quarter 2022 Financial Results and Provides Business Update

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter ended September 30, 2022, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Yahoo | November 3, 2022

Rigel Announces Five Poster Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and Exposition

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the upcoming presentation of five posters highlighting data from the Company's commercial and clinical-stage hematology-oncology portfolio at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 10-13, 2022, in New Orleans, LA, and virtually.

Yahoo | November 3, 2022

Read More 'RIGL' Stories Here

RIGL Price Returns

1-mo 14.40%
3-mo -41.96%
6-mo -49.70%
1-year -66.12%
3-year -61.21%
5-year -78.99%
YTD -68.68%
2021 -24.29%
2020 63.55%
2019 -6.96%
2018 -40.72%
2017 63.03%

Continue Researching RIGL

Here are a few links from around the web to help you further your research on Rigel Pharmaceuticals Inc's stock as an investment opportunity:

Rigel Pharmaceuticals Inc (RIGL) Stock Price | Nasdaq
Rigel Pharmaceuticals Inc (RIGL) Stock Quote, History and News - Yahoo Finance
Rigel Pharmaceuticals Inc (RIGL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6666 seconds.